doi:10.1016/j.virs.2026.06.002

[1]
Yuanyuan Qu, Xueyan Zhang, Meiyu Wang, Lina Sun, Yongzhong Jiang, Cheng Li, Wei Wu, Zhen Chen, Qiangling Yin, Xiaolin Jiang, Yang Liu, Chuan Li, Jiandong Li, Tianlei Ying, Dexin Li, Faxian Zhan, Youchun Wang, Wuxiang Guan, Shiwen Wang, Mifang Liang, 2021: Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants, Virologica Sinica, 36, 934-947. doi: 10.1007/s12250-021-00409-4
[2]
Yuan Zhang, Chunjie Li, Xianliang Ke, Dan Luo, Yan Liu, Quanjiao Chen, Hanzhong Wang, Xiaohui Song, Zhenhua Zheng, 2022: Development of a biosensor assessing SARS-CoV-2 main protease proteolytic activity in living cells for antiviral drugs screening, Virologica Sinica, 37, 459-461. doi: 10.1016/j.virs.2022.04.002
[3]
Leike Zhang, Jia Liu, Ruiyuan Cao, Mingyue Xu, Yan Wu, Weijuan Shang, Xi Wang, Huanyu Zhang, Xiaming Jiang, Yuan Sun, Hengrui Hu, Yufeng Li, Gang Zou, Min Zhang, Lei Zhao, Wei Li, Xiaojia Guo, Xiaomei Zhuang, Xing-Lou Yang, Zheng-Li Shi, Fei Deng, Zhihong Hu, Gengfu Xiao, Manli Wang, Wu Zhong, 2020: Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro, Virologica Sinica, 35, 776-784. doi: 10.1007/s12250-020-00288-1
[4]
Zhao LIU, Zhan-qiu YANG, Hong XIAO, 2010: Antiviral Activity of the Effective Monomers from Folium Isatidis Against Influenza Virus in Vivo, Virologica Sinica, 25, 445-451. doi: 10.1007/s12250-010-3142-0
[5]
Tetiana Krupodorova, Svetlana Rybalko, Victor Barshteyn, 2014: Antiviral activity of Basidiomycete mycelia against influenza type A (serotype H1N1) and herpes simplex virus type 2 in cell culture, Virologica Sinica, 29, 284-290. doi: 10.1007/s12250-014-3486-y
[6]
Haili Zhang, Hongli Jin, Feihu Yan, Yumeng Song, Jiaxin Dai, Cuicui Jiao, Yujie Bai, Jingxuan Sun, Di Liu, Shen Wang, Mengyao Zhang, Jilong Lu, Jingbo Huang, Pei Huang, Yuanyuan Li, Xianzhu Xia, Hualei Wang, 2023: An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV, Virologica Sinica, 38, 244-256. doi: 10.1016/j.virs.2022.12.006
[7]
Changqiao You, Shuai Jiang, Yunyun Ding, Shunxing Ye, Xiaoxiao Zou, Hongming Zhang, Zeqi Li, Fenglin Chen, Yongliang Li, Xingyi Ge, Xinhong Guo, 2024: RNA barcode segments for SARS-CoV-2 identification from HCoVs and SARSr-CoV-2 lineages, Virologica Sinica, 39, 156-168. doi: 10.1016/j.virs.2024.01.006
[8]
Sissy Therese Sonnleitner, Stefanie Sonnleitner, Eva Hinterbichler, Hannah Halbfurter, Dominik B.C. Kopecky, Stephan Koblmüller, Christian Sturmbauer, Wilfried Posch, Gernot Walder, 2022: The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro, Virologica Sinica, 37, 198-207. doi: 10.1016/j.virs.2022.01.029
[9]
Yanxing Cai, Wei Xu, Chenjian Gu, Xia Cai, Di Qu, Lu Lu, Youhua Xie, Shibo Jiang, 2020: Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit, Virologica Sinica, 35, 857-860. doi: 10.1007/s12250-020-00305-3
[10]
Yun-Yun Jin, Hanwen Lin, Liu Cao, Wei-Chen Wu, Yanxi Ji, Liubing Du, Yiling Jiang, Yanchun Xie, Kuijie Tong, Fan Xing, Fuxiang Zheng, Mang Shi, Ji-An Pan, Xiaoxue Peng, Deyin Guo, 2021: A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery, Virologica Sinica, 36, 913-923. doi: 10.1007/s12250-021-00385-9
[11]
杨占秋, 文利, 王征, , , 2003: Antiviral Activity of Algefacient and Anti-inflammatory Against Influenza Virus in vitro and in vivo, Virologica Sinica, 18, 534-537.
[12]
Yan-Feng Yao, Ze-Jun Wang, Ren-Di Jiang, Xue Hu, Hua-Jun Zhang, Yi-Wu Zhou, Ge Gao, Ying Chen, Yun Peng, Mei-Qin Liu, Ya-Nan Zhang, Juan Min, Jia Lu, Xiao-Xiao Gao, Jing Guo, Cheng Peng, Xu-Rui Shen, Qian Li, Kai Zhao, Lian Yang, Xin Wan, Bo Zhang, Wen-Hui Wang, Jia Wu, Peng Zhou, Xing-Lou Yang, Shuo Shen, Chao Shan, Zhi-Ming Yuan, Zheng-Li Shi, 2021: Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates, Virologica Sinica, 36, 879-889. doi: 10.1007/s12250-021-00376-w
[13]
Qianran Wang, Lu Peng, Yanqiu Nie, Yanni Shu, Huajun Zhang, Zidan Song, Yufeng Li, Hengrui Hu, Liushuai Li, Xi Wang, Jia Liu, Jiang Li, Zhengli Shi, Fei Deng, Yu Guo, Yiwu Zhou, Bing Yan, Zhihong Hu, Manli Wang, 2023: Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo, Virologica Sinica, 38, 257-267. doi: 10.1016/j.virs.2022.12.007
[14]
Yuming Li, Yanhong Tang, Xiaoqian Wang, Airu Zhu, Dongdong Liu, Yiyun He, Hu Guo, Jie Zheng, Xinzhuo Liu, Fengyu Chi, Yanqun Wang, Zhen Zhuang, Zhaoyong Zhang, Donglan Liu, Zhao Chen, Fang Li, Wei Ran, Kuai Yu, Dong Wang, Liyan Wen, Jianfen Zhuo, Yanjun Zhang, Yin Xi, Jingxian Zhao, Jincun Zhao, Jing Sun, 2024: Characterization of humoral immune responses against SARS-CoV-2 accessory proteins in infected patients and mouse model, Virologica Sinica, 39, 414-421. doi: 10.1016/j.virs.2024.04.005
[15]
Lu Zhang, Siyu Tian, Jun Dai, Yuanyuan Li, Yu Zhou, Yan Li, Jiao Xu, Shuyun Liu, Zhiwei Lin, Zhaoyong Zhang, Jiantao Chen, Peilan Wei, Jingxian Zhao, Jing Jin, Yanqun Wang, Jincun Zhao, 2024: Trivalent SARS-CoV-2 virus-like particle vaccines exhibit broad-spectrum neutralization and protection against XBB.1 and BA.2.86 variants, Virologica Sinica, 39, 836-839. doi: 10.1016/j.virs.2024.08.005
[16]
Yongran Wu, Ke Hong, Lianguo Ruan, Xiaobo Yang, Jiancheng Zhang, Jiqian Xu, Shangwen Pan, Lehao Ren, Lu Chen, Chaolin Huang, You Shang, 2020: Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study, Virologica Sinica, 35, 768-775. doi: 10.1007/s12250-020-00281-8
[17]
Anthony T. Tan, Joey Ming Er Lim, Antonio Bertoletti, 2022: Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines, Virologica Sinica, 37, 783-785. doi: 10.1016/j.virs.2022.11.002
[18]
Yingjian Li, Xue Tan, Jikai Deng, Xuemei Liu, Qianyun Liu, Zhen Zhang, Xiaoya Huang, Chao Shen, Ke Xu, Li Zhou, Yu Chen, 2024: An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo, Virologica Sinica, 39, 447-458. doi: 10.1016/j.virs.2024.03.009
[19]
Fan Shen, Chun Liang, Cui-Xian Yang, Ying Lu, An-Qi Li, Ying Duan, Mi Zhang, Ren-Rong Tian, Xing-Qi Dong, Yong-Tang Zheng, Wei Pang, 2024: SARS-CoV-2 breakthrough infections following inactivated vaccine vaccination induce few neutralizing antibodies against the currently emerging Omicron XBB variants, Virologica Sinica, 39, 173-176. doi: 10.1016/j.virs.2023.11.007
[20]
Mingqing Lu, Kunpeng Liu, Yun Peng, Zhe Ding, Yingwen Li, Alexander Tendu, Xue Hu, Ge Gao, Weiwei Guo, Hang Liu, Juhong Rao, Jiaxuan Zhao, Miaoyu Chen, Zhiming Yuan, Gary Wong, Chao Shan, Yanfeng Yao, Jiaming Lan, 2022: Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice, Virologica Sinica, 37, 581-590. doi: 10.1016/j.virs.2022.05.006